Entasis Therapeutics Holdings Inc.
| NASDAQ: ETTX | Healthcare / Biotechnology / USA |
| 1.90 | 0 | 0.00 | Vol 191.64K | 1Y Perf -28.89% |
| Apr 16th, 2021 16:00 DELAYED |
| BID | 1.90 | ASK | 1.92 | ||
| Open | 1.91 | Previous Close | 1.90 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 6.25 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 228.95 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 54.02 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 70.89M | Earnings Rating | Strong Buy | |
| Price Range Ratio 52W % | 11.99 | Earnings Date | 6th May 2021 |
Today's Price Range 1.851.93 | 52W Range 1.584.25 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -7.77% | ||
| 1 Month | -35.15% | ||
| 3 Months | -28.03% | ||
| 6 Months | -8.21% | ||
| 1 Year | -28.89% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -194.82 | |||
ROE last 12 Months | -106.93 | |||
ROA (5Y Avg) | -65.89 | |||
ROA last 12 Months | -89.70 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -89.82 | |||
Return on invested Capital Q | -18.25 | |||
Return on invested Capital Y | -103.84 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.80 | ||||
| 1.47 | ||||
| 11.40 | ||||
| - | ||||
| -2.40 | ||||
| -1.89 | ||||
| 1.47 | ||||
| 1.40 | ||||
| 24.93M | ||||
| Forward PE | -1.42 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.40 | ||||
| 7.00 | ||||
| 0.01 | ||||
| 0.03 | ||||
| - | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -662.40 | ||||
| -660.40 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.37 | -0.12 | 67.57 |
| Q03 2020 | -0.51 | -0.37 | 27.45 |
| Q02 2020 | -0.58 | -0.78 | -34.48 |
| Q01 2020 | -1.00 | -1.15 | -15.00 |
| Q04 2019 | -0.99 | -1.06 | -7.07 |
| Q03 2019 | -1.13 | -0.27 | 76.11 |
| Q02 2019 | -0.89 | -1.02 | -14.61 |
| Q01 2019 | -0.93 | -0.99 | -6.45 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.34 | 0.00 | - |
| 6/2021 QR | -0.35 | -2.94 | Negative |
| 12/2021 FY | -1.29 | 3.01 | Positive |
| 12/2022 FY | -1.45 | -2.84 | Negative |
| Next Report Date | 6th May 2021 |
| Estimated EPS Next Report | -0.34 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 191.64K |
| Shares Outstanding | 37.31M |
| Trades Count | 945 |
| Dollar Volume | 1.00M |
| Avg. Volume | 340.95K |
| Avg. Weekly Volume | 163.09K |
| Avg. Monthly Volume | 208.60K |
| Avg. Quarterly Volume | 327.40K |
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) stock closed at 1.9 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 191.65K shares and market capitalization of 70.89M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 47 people. Entasis Therapeutics Holdings Inc. CEO is Manoussos Perros.
The one-year performance of Entasis Therapeutics Holdings Inc. stock is -28.89%, while year-to-date (YTD) performance is -23.08%. ETTX stock has a five-year performance of %. Its 52-week range is between 1.58 and 4.25, which gives ETTX stock a 52-week price range ratio of 11.99%
Entasis Therapeutics Holdings Inc. currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 1.47, a price-to-sale (PS) ratio of 11.40, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -89.70%, a ROC of -89.82% and a ROE of -106.93%. The company’s profit margin is -%, its EBITDA margin is -660.40%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Entasis Therapeutics Holdings Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.34 for the next earnings report. Entasis Therapeutics Holdings Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Entasis Therapeutics Holdings Inc. is Strong Buy (1), with a target price of $6.25, which is +228.95% compared to the current price. The earnings rating for Entasis Therapeutics Holdings Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Entasis Therapeutics Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Entasis Therapeutics Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 26.60, ATR14 : 0.20, CCI20 : -99.85, Chaikin Money Flow : -0.27, MACD : -0.29, Money Flow Index : 28.59, ROC : -9.52, RSI : 36.74, STOCH (14,3) : 15.15, STOCH RSI : 0.28, UO : 43.70, Williams %R : -84.85), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Entasis Therapeutics Holdings Inc. in the last 12-months were:
Entasis Therapeutics Holdings Inc.
Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its products candidate includes Zoliflodacin, ETX0282CPDP, and NBP program.
CEO: Manoussos Perros
Telephone: +1 781 810-0120
Address: 35 Gatehouse Drive, Waltham 02451, MA, US
Number of employees: 47
